Alpha Tau to Participate in May Investor Conferences
Alpha Tau (NASDAQ:DRTS) announced that CFO Raphi Levy will participate in several May 2026 investor conferences, including events hosted by H.C.
Rhea-AI Summary
Alpha Tau (NASDAQ:DRTS) announced that CFO Raphi Levy will participate in several May 2026 investor conferences, including events hosted by H.C. Wainwright, Rothschild & Co Redburn, and Lytham Partners.
The schedule features fireside chats, presentations, and 1x1 investor meetings in New York and via virtual webcast.
Positive
- None.
Negative
- None.
Details
News Market Reaction – DRTS
On May 18, the day this news came out, DRTS closed 3.19% below the previous close.
Data tracked by StockTitan Argus for the May 18 session.
Key Figures
- H.C. Wainwright conference date
- May 19, 2026
- H.C. Wainwright 4th Annual BioConnect Investor Conference participation
- H.C. Wainwright session time
- 10:30–11:00 AM ET
- Fireside chat window at BioConnect Investor Conference
- Rothschild Radiopharma date
- May 27, 2026
- Rothschild & Co Redburn Radiopharma Conference 2026 1x1 meetings
- Lytham conference date
- May 28, 2026
- Lytham Partners Spring 2026 Investor Conference presentation
- Lytham presentation time
- 9:00 AM ET
- Scheduled presentation time at Lytham Partners conference
Historical Context
-
Interim REGAIN trial data with strong local control and complete responses.
-
Announcement of conference call to discuss interim GBM clinical data.
-
Completion of enrollment in U.S. pivotal cSCC study aiming at FDA approval.
-
First pancreatic cancer patient treated in Italy under feasibility protocol.
-
Announcement of future podium presentation on Alpha DaRT plus pembrolizumab.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026.
| Event: | H.C. Wainwright 4th Annual BioConnect Investor Conference |
| Format: | Fireside Chat and 1x1 Meetings |
| Date: | Tuesday, May 19, 2026 |
| Time: | 10:30 – 11:00AM ET |
| Location: | New York, NY |
| Event: | Rothschild & Co Redburn Radiopharma Conference 2026 |
| Format: | 1x1 Meetings |
| Date: | Wednesday, May 27, 2026 |
| Location: | New York, NY |
| Event: | Lytham Partners Spring 2026 Investor Conference |
| Format: | Presentation and 1x1 Meetings |
| Date: | Thursday, May 28, 2026 |
| Time: | 9:00AM ET |
| Location: | Virtual - https://app.webinar.net/Ew6XKl4KQ71 |
Mr. Levy will be available for 1x1 investor meetings at all conferences. Please reach out to your H.C. Wainwright, Rothschild, or Lytham Partners representatives to schedule.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.